Zentalis selected the 400 mg dose of its drug to treat ovarian cancer after it showed a higher response rate than the 300 mg dose. ・The company expects to complete enrollment and report topline ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector's two major indexes - the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) - ...

On February 17, 2026, Boone Capital Management sold out its entire Cogent Biosciences (NASDAQ:COGT) stake, liquidating 945,042 shares previously worth $13.57 million. According to an SEC filing dated ...

On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026. The firm shed light on the biopharma segment, which is entering 2026 with renewed momentum and a ...

Brokers are upbeat and see upside of up to 125%! The post Is this battered ASX biotech stock ready to rocket higher? appeared ...

IBT's Ailsa Craig and Marek Poszepczynski give their key stock picks as companies move on from the science to commercial ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

Biotech stocks saw a major rebound in 2025, with key indexes significantly outperforming the S&P 500. Private investment in longevity science doubled in 2024, highlighting growing interest in ...